ERBB2 and breast carcinoma: In a different study, miR-218-5p was found to have supported the ERBB2 and EGFR expression by inhibiting the LRIG1 in breast cancer cells, which shows that miR-218-5p, and LRIG1can act as an oncogene in breast cancer and can be used as a therapeutic target for breast cancer treatments (Qian et al. 2021).